- Open
- 68.00
- High
- 70.00
- Low
- 67.50
- Close
- 68.63
- Change
- -1.00 (-1.47%)
- Volume
- 679,333
| 9 Jul 2026 | 07:00:04 | Accelerated Amortized Payment of Bond Installment |
| 8 Jul 2026 | 07:00:04 | Avacta Appoints Patrick Vink Deputy Chairman |
| 25 Jun 2026 | 07:00:04 | Platform-Validating Data with Faridoxorubicin |
| 25 Jun 2026 | 07:00:04 | FDA Agreement on Pivotal Trial Design for AVA6000 |
| 23 Jun 2026 | 07:00:03 | Result of AGM |
| 22 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 6 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Avacta Group plc develops novel cancer therapies and advanced diagnostic tools, focusing primarily on oncology therapeutics. The company utilizes its proprietary platforms, Affimer® and pre|CISION™, to create targeted peptide and antibody drug conjugates aimed at improving treatment outcomes while minimizing toxicity. Avacta is transitioning to a pure-play oncology company by divesting its diagnostics division, concentrating on the development of its therapeutic candidates, including AVA6000, AVA6103, and AVA7100, which target solid tumors. The company operates primarily in the biotechnology sector, serving patients with cancer and collaborating with partners in the healthcare industry.
Lord Fink and Lord Stevens of Ludgate have interests in this issuer
| 9 Jul 2026 | 07:00:04 | Accelerated Amortized Payment of Bond Installment |
| 8 Jul 2026 | 07:00:04 | Avacta Appoints Patrick Vink Deputy Chairman |
| 25 Jun 2026 | 07:00:04 | Platform-Validating Data with Faridoxorubicin |
| 25 Jun 2026 | 07:00:04 | FDA Agreement on Pivotal Trial Design for AVA6000 |
| 23 Jun 2026 | 07:00:03 | Result of AGM |
| 22 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 6 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Avacta Group plc develops novel cancer therapies and advanced diagnostic tools, focusing primarily on oncology therapeutics. The company utilizes its proprietary platforms, Affimer® and pre|CISION™, to create targeted peptide and antibody drug conjugates aimed at improving treatment outcomes while minimizing toxicity. Avacta is transitioning to a pure-play oncology company by divesting its diagnostics division, concentrating on the development of its therapeutic candidates, including AVA6000, AVA6103, and AVA7100, which target solid tumors. The company operates primarily in the biotechnology sector, serving patients with cancer and collaborating with partners in the healthcare industry.
Lord Fink and Lord Stevens of Ludgate have interests in this issuer
| Issuer | Mkt cap | 1Y |
|---|---|---|
AVCTAvacta Group PLC | £314m | +0.3% |
| £307m | -0.1% | |
| £48m | -0.3% | |
| £24m | +0.9% | |
| £12m | +0.5% | |
| £902k | -0.2% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
AVCTAvacta Group PLC | £314m | +0.3% |
| £307m | -0.1% | |
| £48m | -0.3% | |
| £24m | +0.9% | |
| £12m | +0.5% | |
| £902k | -0.2% |
